Stomach Cancer News and Research

RSS

Stomach cancer or gastric cancer affects around 7,000 people each year in the UK. Stomach cancer is difficult to detect in the early stages because the initial symptoms are also seen in less serious conditions such as persistent indigestion, heart burn, trapped wind, burping and stomach ache.

Sugar-based vaccine against Helicobacter pylori

A potential vaccine against bacteria that cause serious gastric disorders including stomach cancer may be a step closer following a pioneering study by a University of Guelph chemist.

19 Apr 2011

Viewpoints: Controlling long-term-care spending; march madness and health reform; hospital physicians

Prepare to hear a lot about Medicaid, the government health-insurance program for the poor. ... The U.S. government can't put itself on a sustainable fiscal course without doing something to slow health spending. It can't slow health spending costs without treating Medicaid. And it can't treat Medicaid without confronting the fact that it has become the long-term-care insurer of last resort for an aging society.

1 Apr 2011

Scientists receive £200,000 AICR grant for stomach cancer research

Scientists in Australia have been awarded almost £200,000 from an international charity, based in Scotland, towards their research into a 'forgotten cancer.'

22 Mar 2011

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced today that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase 3 trial of telatinib in combination with chemotherapy for the first-line treatment of patients with advanced stomach cancer.

28 Feb 2011

Trained dog sniffs out colon cancer with 98% accuracy

For the study the researchers at Kyushu University trained an 8-year-old female Labrador retriever named Marine who was given breath and stool samples of 306 patients, collected right before they received colonoscopies.

2 Feb 2011

ACT Biotech releases telatinib Phase 2 trial data for metastatic stomach cancer

ACT Biotech, a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, today released data on additional analysis of the Phase 2 clinical trial of telatinib in patients with metastatic stomach cancer that further supports the highly-potent nature of the antiangiogenic agent.

21 Jan 2011

Procognia grants Euro-Diagnostica license to provide diagnostic services for gastric cancer

Procognia is proud to announce that yesterday it signed a binding memorandum of understanding with Euro-Diagnostica (ED), a European diagnostic company that currently operates in the Scandinavian and Benelux markets, and is expected to expand its activity into other markets which may include Germany, Austria, Switzerland, and the UK in the near future.

23 Dec 2010

Humble aspirin reduces cancer death rates

A new study has shown aspirin cuts down the death rates from a range of cancers. The study reviewed data from eight previous trials involving more than 25,000 patients found that those who took just 75mg of aspirin a day (one-eighth of a normal dose) could reduce their death rates from cancer by 21% with benefits continuing long after patients stopped taking the pill.

7 Dec 2010

T.J. Martell Foundation celebrates 35th Annual Awards Gala to raise funds for cancer and AIDS research

The T.J. Martell Foundation for Leukemia, Cancer and AIDS Research celebrated its 35th Annual Awards Gala on Wednesday, October 27th, 2010 at the New York Marriott Marquis and raised a total of $1.45 million.

29 Oct 2010

LSUHSC receives NIH grant for research on cancer and infectious diseases

LSU Health Sciences Center New Orleans has been awarded $12 million over five years by the National Institutes of Health to conduct research on diseases like prostate and stomach cancers, lymphoma and leukemia, dengue fever, tuberculosis, and herpes infections, as well as to support the development of academic research scientists.

21 Oct 2010

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

Genentech, a member of the Roche Group today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic (cancer that has spread) cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for their metastatic disease.

21 Oct 2010

Cancer cluster among Sydney Harbour Bridge workers triggers investigation

There are reports of a cancer cluster among Sydney Harbour Bridge workers with at least eight known cases that unions believe are linked to the use of lead paint. The Roads and Traffic Authority (RTA) will investigate the matter. Of the eight workers five have already died and all of them had been involved in painting and maintaining the bridge for more than 10 years, the Construction Forestry Mining and Energy Union (CFMEU) said. This included scraping off lead paint, initially with little protective equipment.

14 Oct 2010

ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer

ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.

11 Oct 2010

Scientists discover c-Abl protein role in Parkinson's disease progression

Johns Hopkins scientists have discovered that the over-activation of a single protein may shut down the brain-protecting effects of a molecule and facilitate the most common form of Parkinson's disease.

4 Oct 2010

microRNA 451 enhances treatment response in stomach cancer patients: Research

"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jesús García-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.

15 Sep 2010

Study finds long-term use of bone-strengthening drugs increase risk of oesophageal cancer

People who take bone-strengthening pills called bisphosphonates over a long period of time could be more likely to develop cancer of the oesophagus (gullet), new research suggests.

9 Sep 2010

PDL BioPharma reports revenue guidance of $86 million for 2010 third quarter

PDL BioPharma, Inc. today announced revenue guidance for the third quarter ended September 30, 2010 of approximately $86 million, as compared with actual results of $71.4 million for the third quarter of 2009, a 20 percent year-over-year increase.

2 Sep 2010

Cancer Research UK data finds increase in Oesophageal cancer rates among men

Oesophageal cancer rates in men have risen by 50 per cent over the last 25 years, according to new figures published by Cancer Research UK today.In 1983 around 2,600 men were diagnosed with oesophageal cancer - cancer of the food pipe - and according to the latest figures around 5,100 men were diagnosed with the disease.

30 Aug 2010

Bacterial pathogens require vitamin B6 biosynthesis enzymes for virulence: Study

Scientists have determined that Helicobacter pylori, the bacterium that causes peptic ulcers and some forms of stomach cancer, requires the vitamin B6 to establish and maintain chronic infection, according to research published this week in the online journal mBio-. This finding, along with the identification of the enzyme the microbe requires to utilize the vitamin, could lead to the development of an entirely new class of antibiotics.

20 Aug 2010

HemaQuest commences HQK-1004 global Phase 2 clinical trial in EBV-related malignancies

HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.

11 Aug 2010